SCHEMBL11005407

SCHEMBL11005407

O=C(NO)c1c(Cl)cccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HDAC1 Q13547 4/20 0.55
HDAC3 O15379 3/20 0.55
HDAC2 Q92769 3/20 0.55
HDAC6 Q9UBN7 3/20 0.55
HDAC4 P56524 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55
HDAC5 Q9UQL6 2/20 0.55
HPGD P15428 1/20 0.53
JAK2 O60674 1/20 0.53
CYP3A4 P08684 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
GAA P10253 2/20 0.49
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29044162 0.98 ALDH1A1 (0.54) ALDH1A1HDAC1HDAC3HDAC2HDAC6
SCHEMBL28869679 0.86 GAA (0.65) HPGDJAK2JAK1TYK2GAA
SCHEMBL27336816 0.81 CA12 (0.52) HDAC1HDAC3HDAC2HDAC6HDAC4
SCHEMBL29040264 0.80 PBRM1 (0.54) ALDH1A1HDAC1HDAC3HDAC2HDAC6
SCHEMBL15147845 0.79 ALDH1A1 (0.54) ALDH1A1HPGDJAK2CYP3A4JAK1
SCHEMBL4377125 0.79 ALDH1A1 (0.56) ALDH1A1HPGDJAK2CYP3A4JAK1
SCHEMBL18885417 0.79 ALDH1A1 (0.54) ALDH1A1HPGDJAK2CYP3A4JAK1
SCHEMBL9812099 0.79 TTR (0.49) ALDH1A1HDAC1HDAC3HDAC2HDAC6
SCHEMBL4157657 0.79 DOT1L (0.56) ALDH1A1HPGDJAK2CYP3A4JAK1
SCHEMBL19648319 0.79 ALDH1A1 (0.54) ALDH1A1HPGDJAK2CYP3A4JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041653-A1 COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-02-18 US disclosed
US-20100041653-A1 COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-02-18 US disclosed
EP-0133155-A2 Agent and process for increasing a harvest yield CIBA-GEIGY AG (CH) 1985-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041653-A1 COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS HELZ, MMEL1, GAA ALDH1A1 1515/4885HDAC1 28/4885HDAC3 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.